TheraRadar
Data updated: May 26, 2026

GONITRO (nitroglycerin)

Cardiovascular Approved 2016-06-08
1
Indication
--
Phase 3 Trials
9
Years on Market

Details

Status
Discontinued
First Approved
2016-06-08
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
SUBLINGUAL
Dosage Forms
POWDER

Companies

Active Ingredient: NITROGLYCERIN

GONITRO Approval History

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2016 to 2016
Jun 2016 ORIGINAL
New Form · Type 3 - New Dosage Form

What GONITRO Treats

1 FDA approvals

Originally approved for its first indication in 2016 .

  • Other (1)
📋

Clinical Trial Registry

13 trials
Trial Sponsor ID Phase Status Title
NCT02425566 141218 Ph 1 active not recruiting Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension
NCT03689946 results posted 54274 Ph 3 completed Effect of Evolocumab on Coronary Atherosclerosis
NCT02209636 results posted CLNB-006-13F CX001030 Ph 4 completed Phosphate Lowering in CKD Trial
NCT02617550 VENICE 17849 2015-001444-11 Ph 1 completed Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
NCT03716050 results posted IRB00038262 Ph 2, Ph 3 terminated The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems
NCT03809065 N53-2016 Ph 4 completed Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension
NCT03296670 LSG1501104 Ph 4 completed Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP
NCT04220281 prop RGAbusinna Ph 1, Ph 2 terminated Comparison Between Two Drugs (Propofol and Nitroglycerin as a Hypotensive Agents During Endoscopic Sinus Surgery
NCT02961946 results posted 2016P002417 Ph 4 completed Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality
NCT03622060 NONERAO HerminaHCK Ph 3 completed Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery Occlusion
NCT02343276 results posted ICSC-2015 Ph 3 completed Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs
NCT02327793 PATIS PATIS Version 1.0 Ph 2 completed Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke
NCT02254252 results posted 12604 Ph 4 completed Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GONITRO FDA Label Details

View full patent landscape →
1 OB patents · 1 families · 24 international docs across 7 countries

GONITRO Patents & Exclusivity

Latest Patent: Mar 2032

Patents (1 active)

US9101592 Expires Mar 11, 2032
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for GONITRO

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2032
  • 1 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.